@TopKniFe_B @bhwords Really B? Excited to see that data. Our experience is the opposite here https://t.co/9xSpemvWyI and in unpublished prospective data. Will be good to compare. @bryanacotton1 will have a say no doubt! Disclosure: research funding to id
@bryanacotton1 @JTraumAcuteSurg I disagree my friend. Benefit likely in part due to the short half life of DOACs. On & off faster. Afib & DVT data from many big RCTs argues DOACs >/= warfarin re: preventing thrombotic risk. Disclosure: industry
Rivaroxaban vs warfarin following #trauma & acute care surg: Fewer reversal agents needed, and outcomes same https://t.co/djLqNhEoth
RT @macky_neal: evidence from our group that rivaroxaban no worse (maybe better?) in #trauma & EGS disclosure: industry funded https://t.co…